RBC Capital raised the firm’s price target on Cytokinetics (CYTK) to $119 from $101 and keeps an Outperform rating on the shares after its Q1 results. Investors have not yet fully priced in the speed of Myqorzo’s growth and peak U.S. opportunity in oHCM, where new patient starts are showing very promising trends, nor ACACIA’s substantial opportunity in nHCM where the firm estimates about $1.3B in sales by 2035, the analyst tells investors in a research note.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Maxwell Skor Lifts Cytokinetics Price Target to $103 and Reiterates Buy on Strong Phase 3 ACACIA-HCM Results for Aficamten
- Cytokinetics Earnings Call Highlights Launch, Trial Wins
- Cytokinetics Highlights MYQORZO Progress and Cardiology Pipeline
- Analyst Maintains Buy Rating and $136 Price Target on Aficamten Following Strong Phase 3 ACACIA-HCM Results
- Morning News Wrap-Up, 5/5/26: Today’s Biggest Stock Market Stories!